Search

Displaying results 151 - 160 of 4265 in total
  1. Drug

    Nitrendipine

    go.drugbank.com/drugs/DB01054
    ApprovedWithdrawn

    Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natri...

  2. Drug

    Lercanidipine

    go.drugbank.com/drugs/DB00528
    ApprovedInvestigationalWithdrawn

    Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.

  3. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].

  4. Drug

    Dipivefrin

    go.drugbank.com/drugs/DB00449
    ApprovedWithdrawn

    Dipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).

  5. Drug

    Polyethylene glycol 400

    go.drugbank.com/drugs/DB11077
    ApprovedInvestigational

    Polyethylene glycols (PEGs) are products made of condensed ethylene oxide and water that can contain various derivatives and have various functions. Because many PEG types are hydrophilic, they are favorably used as enhancers of penetrat...

  6. Drug

    Metolazone

    go.drugbank.com/drugs/DB00524
    ApprovedInvestigational

    A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.

  7. Drug

    Tocofersolan

    go.drugbank.com/drugs/DB11635
    Approved

    In addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS]. … It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop.

  8. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    [A259771] Beremagene geperpavec is genetically modified to deliver _COL7A1_, thereby restoring the levels of the COL7 protein.[L46551] … Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

  9. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes. … [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production.

  10. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.